Objective Postoperative radioiodine remnant ablation (RRA) represents an adjunctive
therapeutic modality in patients with differentiated thyroid cancer (DTC). The impact of late …

Purpose To determine whether thyroid-stimulating hormone level≥ 30 mU/L is necessary
for radioiodine (131 I) remnant ablation (RRA) in patients with differentiated thyroid cancer …

Context: In low-risk differentiated thyroid cancer (DTC), postoperative 131I remnant ablation
should employ a minimum effective activity; reports increasingly suggest efficacy of low …

Purpose We determined the reasons for radioiodine thyroid remnant ablation, and the
procedure's necessity based on postsurgical remnant size, in patients with putatively “low …

Objective Postablation whole‐body scintigraphy, which is performed 5–7 days after
administration of ablation activity of radioactive iodine‐131 (131I) in patients with thyroid …

Objective To describe the risk of structural disease recurrence in a cohort of patients with
differentiated thyroid cancer selected for treatment with either thyroid lobectomy or total …

Background: Postsurgical thyrotropin (TSH)-stimulated serum thyroglobulin (Tg) level can be
used to predict the likelihood of finding radioactive iodine (RAI) avid metastatic foci on …

Abstract Background I-131 treatment (RAI) decision relies heavily on serum thyroglobulin
(Tg) levels, as higher Tg levels are assumed to be correlated with higher I-131 uptake. Tg …

Objectives To evaluate the clinical outcomes of persistent radioiodine uptake (RAIU) in the
neck by diagnostic whole body scan (DxWBS) after initial therapy and the efficacy of the …

Radioiodine activity required for remnant thyroid ablation is of great concern, to avoid
unnecessary exposure to radiation and minimize adverse effects. We investigated clinical …